Tvardi Therapeutics is trading 5.26% lower at $1.08, with biotechnology-sector weakness the likeliest explanation; no direct cause for the individual move is confirmed.
- XBI fell 2.50% during the regular session, and market data also showed XBI lower on October 6, 2026.
- No clear company-specific catalyst has been identified for October 6, 2026; the latest listed company announcement predates this session.